{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:54:29Z","timestamp":1787014469695,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T00:00:00Z","timestamp":1256515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T00:00:00Z","timestamp":1256515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1111\/j.1365-2133.2009.09561.x","type":"journal-article","created":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T07:13:47Z","timestamp":1256541227000},"page":"661-668","source":"Crossref","is-referenced-by-count":118,"title":["Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial"],"prefix":"10.1093","volume":"162","author":[{"given":"J.","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"F\u00f6lster-Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,26]]},"reference":[{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMcp042803","article-title":"Clinical practice. Atopic dermatitis","volume":"352","author":"Williams","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2000.107773","article-title":"The prevalence of atopic dermatitis in Oregon schoolchildren","volume":"43","author":"Laughter","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2133.1996.d01-926.x","article-title":"Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study","volume":"135","author":"Herd","year":"1996","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2133.2009.09561.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1067\/mjd.2001.117010","article-title":"Quality of life in atopic dermatitis","volume":"45","author":"Finlay","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2133.2007.08354.x","article-title":"Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema - a population-based study","volume":"158","author":"Schmitt","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl. 6","key":"10.1111\/j.1365-2133.2009.09561.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","article-title":"Atopic dermatitis and the atopic march","volume":"112","author":"Spergel","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jama.2009.136","article-title":"Atopic eczema and attention-deficit\/hyperactivity disorder in a population-based sample of children and adolescents","volume":"301","author":"Schmitt","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2133.2009.09309.x","article-title":"Psychiatric comorbidity in adult eczema","volume":"161","author":"Schmitt","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.18553\/jmcp.2002.8.5.333","article-title":"The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization","volume":"8","author":"Fivenson","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2133.1996.d01-970.x","article-title":"The cost of atopic eczema","volume":"135","author":"Herd","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00105-009-1709-1","article-title":"Significance of atopic dermatitis in outpatient medical care. Analysis of health care data from Saxony","volume":"60","author":"Schmitt","year":"2009","journal-title":"Hautarzt"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000151355","article-title":"Treatment following an evidence-based algorithm versus individualised symptom-oriented treatment for atopic eczema. A randomised controlled trial","volume":"217","author":"Schmitt","year":"2008","journal-title":"Dermatology"},{"issue":"Suppl. 63","key":"10.1111\/j.1365-2133.2009.09561.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2133.148.s63.1.x","article-title":"International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies","volume":"148","author":"Ellis","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB14|cit14","first-page":"345","article-title":"Outpatient care and medical treatment of children and adults with atopic eczema","volume":"7","author":"Schmitt","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2340\/00015555-0207","article-title":"Systemic treatment of severe atopic eczema: a systematic review","volume":"87","author":"Schmitt","year":"2007","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.02023.x","article-title":"Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis","volume":"21","author":"Schmitt","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. Working Party\u2019s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2133.1996.d01-925.x","article-title":"Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party","volume":"135","author":"Williams","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB19|cit19","first-page":"23","article-title":"Consensus Report of the European Task Force on Atopic Dermatitis","volume":"186","author":"Severity scoring of atopic dermatitis: the SCORAD index","year":"1993","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000245677","article-title":"Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis","volume":"195","author":"Kunz","year":"1997","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1087-0024.2004.09113.x","article-title":"10\u2003years experience of the Dermatology Life Quality Index (DLQI)","volume":"9","author":"Lewis","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB23|cit23","volume-title":"Neurodermitis. Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG) und des Berufsverbandes Deutscher Dermatologen (BVDD)","author":"Werfel","year":"2008"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB24|cit24","first-page":"144","volume-title":"Evidence Based Dermatology","author":"Williams","year":"2003"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB25|cit25","first-page":"411","volume-title":"Therapeutische Verfahren in der Dermatologie","author":"Nieder","year":"2001"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0140-6736(03)12193-9","article-title":"Atopic dermatitis","volume":"361","author":"Leung","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB27|cit27","first-page":"1180","volume-title":"Fitzpatrick\u2019s Dermatology in General Medicine","author":"Leung","year":"2003"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"issue":"Suppl. 62","key":"10.1111\/j.1365-2133.2009.09561.x-BIB29|cit29","first-page":"50","article-title":"Clinical meaning of change in Dermatology Life Quality Index Scores","volume":"147","author":"Khilij","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000018065","article-title":"Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study","volume":"198","author":"Zurbriggen","year":"1999","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"Van Joost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2133.1995.tb08633.x","article-title":"Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy","volume":"132","author":"Granlund","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaci.2007.08.011","article-title":"What are the best outcome measurements for atopic eczema? - A systematic review","volume":"120","author":"Schmitt","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2133.2007.08412.x","article-title":"Diagnostic criteria for atopic dermatitis: a systematic review","volume":"158","author":"Brenninkmeijer","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09561.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.2000.03667.x","article-title":"Treatment of atopic eczema with oral mycophenolate mofetil","volume":"143","author":"Neuber","year":"2000","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09561.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09561.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09561.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T04:26:19Z","timestamp":1710649579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/162\/3\/661\/6642399"}},"subtitle":["Prednisolone vs. ciclosporin for eczema"],"short-title":[],"issued":{"date-parts":[[2009,10,26]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09561.x","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,26]]}}}